Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price target at $82.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on the promising clinical data and strategic advancements made by CG Oncology, Inc. The company’s lead asset, cretostimogene, showcased impressive results in the pivotal BOND-003 trial for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), achieving a notable 12-month complete response rate. Additionally, the safety profile of cretostimogene appears favorable compared to its main competitor, TAR-200, as it reported no Grade 3 or higher treatment-related adverse events, which is a significant advantage in the treatment landscape.
Furthermore, CG Oncology is actively expanding its research into other bladder cancer settings, with ongoing trials and expected data releases that could further bolster its market position. The anticipated submission of a Biologics License Application (BLA) for cretostimogene in the fourth quarter of 2025, along with the company’s continued exploration of combination therapies, underscores its commitment to addressing unmet medical needs in bladder cancer treatment. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s growth potential and innovative approach.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 9.2% and a 36.87% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and DBV Technologies SA – American.